Protocolo diagnóstico de las toxicodermias

  1. Burgos Blasco, P. 1
  2. Melián Olivera, A. 1
  3. Selda Enríquez, G. 1
  4. Jaén Olasolo, P. 1
  1. 1 Servicio de Dermatología. Hospital Universitario Ramón y Cajal. IRYCIS. Madrid. España
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2022

Titel der Ausgabe: Enfermedades de la piel (II)

Serie: 13

Nummer: 48

Seiten: 2825-2829

Art: Artikel

DOI: 10.1016/J.MED.2022.02.006 DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Ziele für nachhaltige Entwicklung

Zusammenfassung

The skin is one of the main targets through which adverse drug effects manifest. The incidence of these reactions is rising due to the progressive availability of a greater number of drugs. Clinically, these drugs can trigger any type of skin reaction, from the mildest, such as nonspecific morbilliform exanthematous drug eruption, to severe reactions such as toxic epidermal necrolysis. When faced with toxicoderma, clinical suspicion is fundamental to making an early diagnosis and identification of the drug suspected to be responsible for the reaction in order to suspend it

Bibliographische Referenzen

  • Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.
  • Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select. 2017;1(1):96-108.
  • Drago F, Cogorno L, Agnoletti AF, Ciccarese G, Parodi A. A retrospective study of cutaneous drug reactions in an outpatient population. Int J Clin Pharm. 2015;37(5):739-43.
  • Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases. J Am Acad Dermatol. 2010;62(4):541-55.
  • Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F. Mild cutaneous reactions to drugs. Acta Biomed. 2019;90(3-S):36-43.
  • Duong TA, Valeyrie Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017; 390(10106): 1996-2011.
  • Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843-8.
  • Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca López N. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-53.
  • Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. 2019;58(9):1069-7
Fuente de los datos: Dialnet